Key result
Dual endothelin A/B receptor antagonism blunts pressor responses to acute stress in overweight and obese individuals.
Why the study?
Does dual endothelin A/B receptor antagonism with bosentan blunt the pressor response to acute stress in overweight/obese individuals?
Does dual endothelin A/B receptor antagonism with bosentan blunt the pressor response to acute stress in overweight/obese individuals?
Dual endothelin A/B receptor antagonism with bosentan blunts the exaggerated pressor response to acute stress in overweight and obese individuals, suggesting a potential therapeutic target for reducing cardiovascular disease risk.
Supports endothelin antagonism to mitigate acute CV strain in obesity; extends its role beyond pulmonary hypertension.
Findings from our current translational investigation demonstrate that dual endothelin A/B receptor antagonism blunts the pressor response to acute stress in overweight/obese individuals. These results suggest that modulation of the endothelin system may represent a novel therapeutic target to reduce cardiovascular disease (CVD) risk by blunting the stress response in overweight/obese individuals.
No takes yet. Share an insight, caveat, or question.
Derella et al. (2021) studied Obesity and overweight. Dual endothelin A/B receptor antagonism was evaluated on Pressor response to acute stress. Dual endothelin A/B receptor antagonism blunts the pressor response to acute stress in overweight and obese individuals.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: